EGRET-AAA

You are on home , Visio International , International knowledge development and innovation , International projects , Current projects , EGRET-AAA
Focus Glaucoma research and training
Funding programme European Union: Horizon 2020: Marie Skłodowska-Curie Actions programme
Project coördinator Universitair Medisch Centrum Groningen (Netherlands)
Partners Belgium: Plateforme Européenne Des Femmes Scientifiques AISBL 
France: Sorbonne Université
Germany: Otto von Guericke Universität Magdeburg; Carl von Ossietzky Universität Oldenburg; Imedos Health GmbH; EUROGRANT GmbH; Heidelberg Engineering GmbH; Pro Retina Deutschland 
Netherlands: Academisch Centrum Universiteit Amsterdam; MindAffect BV; Stichting Radboud Universiteit; Oogvereniging Nederland; Siemens Healthineers; AMO Groningen BV; Rijksuniversiteit Groningen; Universiteit van Amsterdam; Royal Dutch Visio
Norway: Bulbitech AS; Universitetet i Oslo 
USA: University of Texas System
Total funding € 1,097,481
Duration February 2023 - January 2027
Website https://www.egret-aaa.eu/ 

 

Glaucoma is an eye condition associated with damage of the optic nerve that connects the eye to the brain. Unless treated early, glaucoma progresses and can lead to vision loss. Millions of people around the world suffer from this condition.

EGRET-AAA, or the European Glaucoma REsearch Training program for Accelerating the Approach to Advanced Glaucoma, aims to develop innovative treatments for glaucoma. We ultimately hope to save around 1 million Europeans from blindness, and another 5 million from significant vision loss.

The project offers doctorate programmes for young researchers to investigate gene therapy and stem cell-based approaches for glaucoma using organoid technology. These researchers will develop innovative treatments to protect and restore vision in patients with glaucoma. 

The research focuses on three aspects:

  • Emerging therapies in advanced glaucoma: stem cell and gene therapeutic approaches, furthering gene and stem cell-based treatment for advanced glaucoma using human retinal organoids.
  • Healthy retinal environment: neuroprotection and oxygen delivery, to develop new methods to offer remaining and new ganglion cells a healthy environment in terms of oxygen delivery and neuroprotection.
  • Assessment of structure and function in advanced glaucoma, to develop techniques to assess changes in retinal and visual pathway structure and function in advanced glaucoma.